Gujarat Terce Laboratories Ltd
BSE: GUJTERC · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Gujarat Terce Laboratories Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gujarat Terce Laboratories Limited is an Ahmedabad-based pharmaceutical company engaged in the manufacturing, marketing, and distribution of diverse pharmaceutical formulations. Its product portfolio covers therapeutic segments such as antibiotics, respiratory, nutraceuticals, gastrointestinal, and pain management.
Business Model
The company operates a B2B and B2C model, leveraging a dedicated field force to market products directly to healthcare professionals and retail pharmacies. It utilizes a network of stockists and distributors to ensure product availability across various Indian states.
Management Commentary
Management focuses on providing affordable healthcare solutions, particularly within the pediatric and gynecology segments. The company maintains its manufacturing operations in Mehsana in compliance with Good Manufacturing Practice standards.
Growth Outlook
Growth is driven by the expansion of its established brands in the pediatric and gynecology segments and the strengthening of its distribution network. The company aims to leverage its domestic market presence to increase penetration in the Indian pharmaceutical sector.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining Good Manufacturing Practice standards and evolving pharmaceutical regulations in India.
- Market Competition. Intense competition from both large-scale pharmaceutical manufacturers and other small-cap entities may impact pricing power and market share.
- Supply Chain Dependencies. Reliance on a network of stockists and distributors exposes the company to potential disruptions in the supply chain and logistics.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can adversely affect profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Gujarat Terce Laboratories Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹47 Cr
TTM · standalone
NET PROFIT
₹2 Cr
TTM · standalone
EPS
₹3.03
TTM · standalone
RETURN ON EQUITY
31.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
30.5%
TTM · standalone
P/E
11.4x
Q4 FY26 · standalone
EV/EBITDA
6.2x
Q4 FY26 · standalone
EBITDA MARGIN
9.0%
TTM · standalone
NET PROFIT MARGIN
0.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Gujarat Terce Laboratories LtdGUJTERC | ₹30 Cr | 12.66 | 6.65 | -5.4% | 9.0% | 31.5% | 30.5% | -5.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Gujarat Terce Laboratories Ltd
BSE: GUJTERC · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Gujarat Terce Laboratories Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gujarat Terce Laboratories Limited is an Ahmedabad-based pharmaceutical company engaged in the manufacturing, marketing, and distribution of diverse pharmaceutical formulations. Its product portfolio covers therapeutic segments such as antibiotics, respiratory, nutraceuticals, gastrointestinal, and pain management.
Business Model
The company operates a B2B and B2C model, leveraging a dedicated field force to market products directly to healthcare professionals and retail pharmacies. It utilizes a network of stockists and distributors to ensure product availability across various Indian states.
Management Commentary
Management focuses on providing affordable healthcare solutions, particularly within the pediatric and gynecology segments. The company maintains its manufacturing operations in Mehsana in compliance with Good Manufacturing Practice standards.
Growth Outlook
Growth is driven by the expansion of its established brands in the pediatric and gynecology segments and the strengthening of its distribution network. The company aims to leverage its domestic market presence to increase penetration in the Indian pharmaceutical sector.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining Good Manufacturing Practice standards and evolving pharmaceutical regulations in India.
- Market Competition. Intense competition from both large-scale pharmaceutical manufacturers and other small-cap entities may impact pricing power and market share.
- Supply Chain Dependencies. Reliance on a network of stockists and distributors exposes the company to potential disruptions in the supply chain and logistics.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can adversely affect profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Gujarat Terce Laboratories Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹47 Cr
TTM · standalone
NET PROFIT
₹2 Cr
TTM · standalone
EPS
₹3.03
TTM · standalone
RETURN ON EQUITY
31.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
30.5%
TTM · standalone
P/E
11.4x
Q4 FY26 · standalone
EV/EBITDA
6.2x
Q4 FY26 · standalone
EBITDA MARGIN
9.0%
TTM · standalone
NET PROFIT MARGIN
0.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26